RXRX — RECURSION PHARMACEUTICALS IN

Ownership history in Focus Partners Wealth  ·  3 quarters on record

This page tracks every 13F SEC filing in which Focus Partners Wealth reported a position in RECURSION PHARMACEUTICALS IN (RXRX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 ADDED 18,555 +4,215 +29.4% 0.00% $91K $4.88
2025 Q2 REDUCED 14,340 -214 -1.5% 0.00% $73K $5.06
2025 Q1 INITIATED 14,554 — — 0.00% $77K $5.29
% of Fund (quarterly)    RXRX price (monthly, adj. close)

Other funds also holding RXRX

As of 2025 Q4 — sorted by position size

DCVC Opportunity Fund II GP, LLC 3Y 97.42% Data Collective IV GP, LLC 3Y 41.53% MIC Capital Management UK LLP 3Y 8.94% Nan Fung Group Holdings Ltd 3Y 2.18% ARK Investment Management LLC 3Y 7Y 1.01% Pivotal bioVenture Partners Investment Advisor LLC 3Y 0.94% Carroll Investors, Inc 3Y 0.79% IQ EQ FUND MANAGEMENT (IRELAND) Ltd 3Y 7Y 0.68% Green Alpha Advisors, LLC 3Y 0.57% Lingotto Investment Management LLP 3Y 7Y 0.35%
← Back to Focus Partners Wealth Holdings